Results 121 to 130 of about 912,080 (293)

Genetics of Growth Disorders—Which Patients Require Genetic Testing? [PDF]

, 2019
Jesús Argente, Katrina Tatton‐Brown, Dagmar Lehwalder, Roland Pfäffle   +3 more
openalex   +1 more source

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism

Molecular Oncology, EarlyView.
Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.
Adrien M. Vaquié, Davod R. Shah, Eliane E. S. Brechbühl, Michael McNicholas, Zhaoyang Xu, John H. Stockley, Laura Morcom, Diana Gold Diaz, Gemma C. Girdler, Rachel V. Seear, Gabriel Balmus, Rajiv R. Ratan, Harry Bulstrode, James A. Nathan, Manav Pathania, Kevin M. Brindle, David H. Rowitch   +16 more
wiley   +1 more source

A Review on Dapsone Hypersensitivity Syndrome Among Chinese Patients with an Emphasis on Preventing Adverse Drug Reactions with Genetic Testing [PDF]

, 2017
Na Wang, Leela Rani Parimi, Hong Liu, Furen Zhang   +3 more
openalex   +1 more source

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source

244 Novel respirable antisense oligonucleotide (RASON) approach to primary and metastatic human lung cancer: preliminary results in a model system employing spontaneous lung tumors in dogs

Journal for ImmunoTherapy of Cancer, 2020
Jonathan Nyce
doaj   +1 more source

The Indication of Genetic Testing for the Children with Long QT Intervals

, 2020
Gaku Izumi
openalex   +2 more sources

Analysing DNA patents in relation with diagnostic genetic testing [PDF]

, 2005
Birgit Verbeure, Gert Matthijs, Geertrui Van Overwalle   +2 more
openalex   +1 more source

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

Molecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad, Rhiannon Newman, Elmira Khabusheva, Sofia Aakko, Eric Durand, Mahesh Tambe, Heikki Kuusanmäki, Alun Parsons, Juho J. Miettinen, Komal Kumar Javarappa, Ezgi June Olgac, Nemo Ikonen, Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman   +17 more
wiley   +1 more source

Genetic diversity analysis and the genetic fingerprinting of 33 DUS test standard tobacco varieties [PDF]

, 2020
Binbin He, Ruimei Geng, Li-Rui CHENG, Xianbin Yang, Hongmei Ge, Min Ren   +5 more
openalex   +1 more source

To (genetic) test or not to test, that is the question [PDF]

Journal of Comparative Effectiveness Research, 2015
openaire   +2 more sources